ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Nonprofits invest in tackling drug-resistant bacteria

by Lisa M. Jarvis
March 23, 2019 | APPEARED IN VOLUME 97, ISSUE 12

 

Nonprofits are expanding their efforts to tackle the most pernicious superbugs. Germany’s Federal Ministry of Education and Research had committed €39 million ($45 million) over four years to Carb-X, a partnership that is developing antibiotics, vaccines, and diagnostics for drug-resistant bacteria. With the investment, Carb-X says its funding now totals up to $550 million. Separately, the Global Antibiotic Research and Development Partnership (GARDP) has teamed with Evotec to speed development of novel antibiotics for resistant infections. The partners will leverage Evotec’s drug-discovery experience and GARDP’s clinical expertise.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment